May 2018 – Cancer Biomarkers and Molecular Testing
On February 14, 2018, the FDA approved Erleada (apalutamide; from Janssen) for the treatment of patients with nonmetastatic, castration-resistant prostate cancer. Read More ›
The CDK4/CDK6 inhibitor Verzenio received a new indication, for use alone or in combination with an aromatase inhibitor, as initial therapy in women with HR-positive, HER2-negative advanced or metastatic breast cancer. Read More ›
This is the first time the FDA has used minimal residual disease (MRD) as a biomarker to approve a specific treatment for patients with acute lymphoblastic leukemia (ALL). Read More ›
A national advocacy program trains patients with metastatic breast cancer to educate the public about the special needs of patients with advanced breast cancer. Read More ›